Evidence map›Paper›PMID 24959384›Full record

ArticleAmerican journal of cancer research2014

Genome-wide copy number analysis in pediatric glioblastoma multiforme.

Laura Giunti, Marilena Pantaleo, Iacopo Sardi, Aldesia Provenzano, Alberto Magi, Stefania Cardellicchio, Francesca Castiglione, Lorenzo Tattini, Francesca Novara, Anna Maria Buccoliero and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Laura GiuntiMedical Genetics Unit, Meyer Children's University Hospital Florence, Italy.
Marilena PantaleoMedical Genetics Unit, Meyer Children's University Hospital Florence, Italy.
Iacopo SardiNeuro-Oncology Unit, Department of Pediatrics, Meyer Children's Hospital Florence, Italy.
Aldesia ProvenzanoDepartment of Clinical and Experimental Biomedical Sciences "Mario Serio", University of Florence Florence, Italy.
Alberto MagiDepartment of Clinical and Experimental Medicine, University of Florence Florence, Italy.
Stefania CardellicchioNeuro-Oncology Unit, Department of Pediatrics, Meyer Children's Hospital Florence, Italy.
Francesca CastiglioneDepartment of Clinical and Experimental Medicine, University of Florence Florence, Italy.
Lorenzo TattiniDepartment of Clinical and Experimental Medicine, University of Florence Florence, Italy ; Laboratory of Molecular Genetics, G. Gaslini Institute Genova, Italy.
Francesca NovaraDepartment of Molecular Medicine, University of Pavia Pavia, Italy.
Anna Maria BuccolieroAnatomic Pathology Unit, Meyer Children's University Hospital Florence, Italy.
Maurizio de MartinoNeurosurgery Unit, Department of Neuroscience, Meyer Children's Hospital Florence, Italy.
Lorenzo GenitoriDepartment of Health Sciences, University of Florence Florence, Italy.
Orsetta ZuffardiDepartment of Molecular Medicine, University of Pavia Pavia, Italy.
Sabrina GiglioMedical Genetics Unit, Meyer Children's University Hospital Florence, Italy ; Department of Clinical and Experimental Biomedical Sciences "Mario Serio", University of Florence Florence, Italy ; FiorGen Foundation for Pharmacogenomics Sesto Fiorentino, Italy.
University of Pavia · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a very aggressive and lethal brain tumor with poor prognosis. Despite new treatment strategies, patients' median survival is still less than 1 year in most cases. Few studies have focused exclusively on this disease in children and most of our understanding of the disease process and its clinical outcome has come from studies on malignant gliomas in childhood, combining children with the diagnosis of GBM with other pediatric patients harboring high grade malignant tumors other than GBM. In this study we investigated, using array-CGH platforms, children (median age of 9 years) affected by GBM (WHO-grade IV). We identified recurrent Copy Number Alterations demonstrating that different chromosome regions are involved, in various combinations. These observations suggest a condition of strong genomic instability. Since cancer is an acquired disease and inherited factors play a significant role, we compared for the first time the constitutional Copy Number Variations with the Copy Number Alterations found in tumor biopsy. We speculate that genes included in the recurrent 9p21.3 and 16p13.3 deletions and 1q32.1-q44 duplication play a crucial role for tumorigenesis and/or progression. In particular we suggest that the A2BP1 gene (16p13.3) is one possible culprit of the disease. Given the rarity of the disease, the poor quality and quantity of bioptic material and the scarcity of data in the literature, our findings may better elucidate the genomic background of these tumors. The recognition of candidate genes underlying this disease could then improve treatment strategies for this devastating tumor.

Indexed as

amplificationarray-CGHcentral nervous tumorcopy number alterations (CNA)copy number variations (CNVs)deletionduplicationminimum common regionsPediatric glioblastoma multiformetumorigenesis

Identifiers

PMID24959384
PMCPMC4065410
OpenAlexW326268875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.